Results 11 to 20 of about 41,661 (291)
Androgen Deprivation Therapy for Prostate Cancer [PDF]
JAMA, 2005 Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in US men. Androgen deprivation therapy (ADT), specifically surgical or medical castration, is the first line of treatment against advanced prostate cancer and is also used as an adjuvant to local treatment of high-risk disease.To review systematically ...
Nima, Sharifi +2 more
openaire +3 more sources
Androgen Deprivation Therapy Toxicity and Management for Men Receiving Radiation Therapy
Prostate Cancer, 2012 Androgen deprivation therapy is commonly used in combination with radiotherapy as part of the definitive treatment for men with clinically localized and locally advanced prostate cancer.
Matthew E. Johnson, Mark K. Buyyounouski
doaj +2 more sources
Androgen Deprivation Causes Epithelial–Mesenchymal Transition in the Prostate: Implications for Androgen-Deprivation Therapy [PDF]
Cancer Research, 2012 Abstract Androgen deprivation is currently a standard-of-care, first-line therapy for prostate cancer in the United States. Although this regimen effectively regresses androgen-dependent disease, relapse often occurs in an androgen-independent manner and is associated with poor prognosis.
Yuting, Sun +11 more
openaire +3 more sources
Žurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, 2018 Background. The efficacy of combined radiation therapy with high dose rate brachytherapy in prostate cancer remains poorly understood. Purpose of the study: To evaluate the effectiveness of combined radiotherapy of prostate cancer and androgen ...
Auchynikau V. A. +2 more
doaj +2 more sources
Androgen Deprivation Therapy for Prostate Cancer
, 2018 In the contemporary scene, less than 5% of men with newly diagnosed prostate cancer (PC) have metastases at first presentation, compared to 20-25%, more than 20 years ago. Nonetheless, the use of androgen deprivation therapy (ADT) has increased over the years, suggesting that patients in Europe and United States may receive ADT in cases of lower ...
Pagliarulo V., Vincenzo Pagliarulo
openaire +4 more sources
HbA1c variability and cardiovascular events in patients with prostate cancer receiving androgen deprivation therapy [PDF]
, 2022 Androgen deprivation therapy (ADT) worsens glycaemic control and cardiovascular outcomes. The prognostic value of visit-to-visit HbA1c variability (VVHV) has been unexplored in prostate cancer (PCa) patients receiving ADT. To explore the effect of ADT on
Tse, Gary +9 more
core +1 more source
A Case of Relugolix-Associated Rhabdomyolysis
Annals of Internal Medicine: Clinical Cases, 2023 Androgen deprivation therapy is an integral component of systemic therapy for advanced prostate cancer. However, androgen deprivation therapy causes an array of adverse events secondary to castrate levels of testosterone.
Benjamin Tanenbaum +3 more
doaj +1 more source
F1000Research, 2022 Background: Although intermittent androgen deprivation therapy was introduced many years ago to improve patients’ quality of life with the same carcinologic efficiency as continuous hormonal therapy, recent data suggest that intermittency could be ...
Iratxe Urreta +7 more
doaj +1 more source
Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer [PDF]
, 2001 Objective To examine the role of androgen receptor (AR) gene amplification and aneusomy of the X chromosome in the development of antiandrogen-resistant prostate cancer.
Watters, A.D. +5 more
core +1 more source
The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor [PDF]
, 2005 Prostate cancer is the second most common male malignancy in the western world an increasing incidence in an ageing population. Treatment of advanced prostate cancer relies on androgen deprivation.
Edwards, J., Bartlett, J.M.S.
core +1 more source